[Pharmacological and clinical profile of gabapentin enacarbil: a novel drug for the treatment of restless legs syndrome]

Nihon Yakurigaku Zasshi. 2012 Aug;140(2):85-92. doi: 10.1254/fpj.140.85.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Animals
  • Biological Availability
  • Carbamates / adverse effects
  • Carbamates / pharmacokinetics
  • Carbamates / pharmacology
  • Carbamates / therapeutic use*
  • Clinical Trials as Topic
  • Humans
  • Prodrugs / adverse effects
  • Prodrugs / pharmacokinetics
  • Prodrugs / pharmacology
  • Prodrugs / therapeutic use*
  • Rats
  • Restless Legs Syndrome / drug therapy*
  • Restless Legs Syndrome / etiology
  • Treatment Outcome
  • gamma-Aminobutyric Acid / adverse effects
  • gamma-Aminobutyric Acid / analogs & derivatives*
  • gamma-Aminobutyric Acid / pharmacokinetics
  • gamma-Aminobutyric Acid / pharmacology
  • gamma-Aminobutyric Acid / therapeutic use

Substances

  • 1-(((alpha-isobutanoyloxyethoxy)carbonyl)aminomethyl)-1-cyclohexaneacetic acid
  • Carbamates
  • Prodrugs
  • gamma-Aminobutyric Acid